Site-specific glycan analysis of the SARS-CoV-2 spike

Authors :: Joel D. Allen
Daniel Wrapp
Jason S. McLellan
Yasunori Watanabe
Max Crispin
Source :: Science, bioRxiv, article-version (status) pre, article-version (number) 1, Science (New York, N.y.)
Publication Year :: 2020
Publisher :: American Association for the Advancement of Science (AAAS), 2020.
Abstract: SARS-CoV-2 spike protein, elaborated Vaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes from antibody neutralization. Watanabe et al. expressed and purified recombinant glycosylated spike trimers, proteolysed them to yield glycopeptides containing a single glycan, and determined the composition of the glycan sites by mass spectrometry. The analysis provides a benchmark that can be used to measure antigen quality as vaccines and antibody tests are developed. Science this issue p. 330